Target intelligence / Profile preview

Viral surface glycoprotein

Molecular classification
Glycoprotein, Viral protein, Receptor ligand, Fusion protein
01

Overview

Viral surface glycoproteins are critical structural components of enveloped viruses that reside on the exterior of the virion, where they mediate the initial stages of the viral life cycle. These proteins are primarily responsible for recognizing and binding to specific receptors on the host cell surface, followed by the orchestration of membrane fusion to allow the viral genome to enter the cytoplasm (PMID: 31513344). Because they are the most exposed viral elements, they serve as the principal targets for the host's neutralizing antibody response and are the primary antigens used in vaccine development (PMID: 35711413). To survive immune pressure, many viral glycoproteins have evolved mechanisms such as high mutation rates (antigenic drift) and extensive N-linked glycosylation, known as glycan shielding, which masks conserved epitopes from antibody recognition (PMID: 17307400). Therapeutic strategies targeting these proteins include monoclonal antibodies that neutralize the virus, small molecule inhibitors that block attachment or fusion, and lectins that bind to surface glycans (PMID: 12633313). Prominent examples include the Spike protein of SARS-CoV-2, Hemagglutinin of Influenza, and the gp120/gp41 complex of HIV-1.

Other names
Envelope glycoproteinSpike proteinSurface antigenViral attachment proteinFusion proteinPeplomer
02

Mechanism of action

Neutralization, Viral entry inhibition, Fusion inhibition, Attachment inhibition

03

Biological functions

Viral attachmentMembrane fusionCell entryImmune evasionHost cell recognitionGlycan shielding
04

Disease associations

InfectionViral hemorrhagic feverRespiratory tract infectionAcquired immunodeficiency syndromeCOVID-19Influenza
05

Safety considerations

Antigenic driftAntigenic shiftAntibody-dependent enhancement (ADE)Viral escape mutationsGlycan shieldingCross-reactivity with host glycans
06

Interacting drugs

Enfuvirtide

8 more in the full profile.

07

Biomarkers

Neutralizing antibody titerViral loadSerum antigen levels (e.g., S-antigen, p24)Hemagglutination inhibition (HI) titer

Beyond the preview

Go deeper on Viral surface glycoprotein.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Viral surface glycoprotein.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call